Singapore, [29 May 2025] – China Life Insurance (Singapore) Pte. Ltd. (“China Life Singapore”) and Singapore Institute of Advanced Medicine Holdings Ltd (“SAM Holdings”) have signed a Memorandum of Understanding (MOU) to establish a long-term and comprehensive strategic partnership. This collaboration marks a significant step toward integrating insurance and healthcare services for enhanced customer value.
Under the agreement, both parties will work together across multiple areas, including client referrals, preferential medical services, knowledge exchange, and professional consultancy.
One of the key initiatives under this partnership is the Client Referral Program, through which China Life customers in Singapore and China who seek medical services from SAM Holdings will enjoy preferential pricing. This includes access to advanced treatment options such as proton therapy and comprehensive health screening packages.
The partnership also includes a series of Regular Sharing Sessions, such as the “Visiting China Life Singapore” initiative, to facilitate continuous knowledge exchange. These sessions will highlight the latest medical innovations and technologies from SAM Holdings, strengthening professional collaboration and customer education.
Additionally, both parties are committed to the development of new areas in medical collaboration. China Life Singapore and SAM Holdings will jointly explore emerging healthcare fields, driving innovation and creating lasting value through integrated efforts.
Through complementary strengths and a shared vision, China Life Singapore and SAM Holdings are building a forward-looking, efficient, and sustainable health protection model that benefits our customers and patients.
